CA3174557A1 - Class ii, type v crispr systems - Google Patents

Class ii, type v crispr systems

Info

Publication number
CA3174557A1
CA3174557A1 CA3174557A CA3174557A CA3174557A1 CA 3174557 A1 CA3174557 A1 CA 3174557A1 CA 3174557 A CA3174557 A CA 3174557A CA 3174557 A CA3174557 A CA 3174557A CA 3174557 A1 CA3174557 A1 CA 3174557A1
Authority
CA
Canada
Prior art keywords
sequence
endonuclease
engineered
guide rna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174557A
Other languages
English (en)
French (fr)
Inventor
Brian Thomas
Christopher Brown
Audra DEVOTO
Cristina Butterfield
Lisa ALEXANDER
Daniela S.A. Goltsman
Justine ALBERS
Alan Brooks
Greg COST
Morayma TEMOCHE-DIAZ
Cindy CASTELLE
Rebecca LAMOTHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metagenomi Inc
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of CA3174557A1 publication Critical patent/CA3174557A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1068Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Amplifiers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3174557A 2020-03-06 2021-03-06 Class ii, type v crispr systems Pending CA3174557A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062986477P 2020-03-06 2020-03-06
US62/986,477 2020-03-06
US202063022276P 2020-05-08 2020-05-08
US63/022,276 2020-05-08
US202063045815P 2020-06-29 2020-06-29
US63/045,815 2020-06-29
US202063068316P 2020-08-20 2020-08-20
US63/068,316 2020-08-20
US202063069699P 2020-08-24 2020-08-24
US63/069,699 2020-08-24
US202063116157P 2020-11-19 2020-11-19
US63/116,157 2020-11-19
PCT/US2021/021259 WO2021178933A2 (en) 2020-03-06 2021-03-06 Class ii, type v crispr systems

Publications (1)

Publication Number Publication Date
CA3174557A1 true CA3174557A1 (en) 2021-09-10

Family

ID=77612848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174557A Pending CA3174557A1 (en) 2020-03-06 2021-03-06 Class ii, type v crispr systems

Country Status (10)

Country Link
US (3) US11713471B2 (ko)
EP (1) EP4114932A4 (ko)
JP (1) JP2023517041A (ko)
KR (2) KR20240036729A (ko)
CN (1) CN116096876A (ko)
AU (2) AU2021231074C1 (ko)
CA (1) CA3174557A1 (ko)
GB (2) GB2603704B (ko)
MX (1) MX2022011039A (ko)
WO (1) WO2021178933A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028729A1 (en) 2018-08-01 2020-02-06 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
CA3174557A1 (en) 2020-03-06 2021-09-10 Metagenomi, Inc. Class ii, type v crispr systems
AU2021368740A1 (en) * 2020-10-30 2023-06-01 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
US11332742B1 (en) * 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
BR112023024983A2 (pt) * 2021-06-02 2024-04-30 Metagenomi Inc Sistemas crispr classe ii, tipo v
EP4408995A1 (en) * 2021-09-28 2024-08-07 Acrigen Biosciences Compositions and methods for nucleic acid modifications
CN115851666B (zh) * 2021-10-29 2023-09-08 山东舜丰生物科技有限公司 新型Cas酶和系统以及应用
WO2023092132A1 (en) * 2021-11-22 2023-05-25 Mammoth Biosciences, Inc. Effector proteins and uses thereof
WO2023141590A2 (en) * 2022-01-21 2023-07-27 Mammoth Biosciences, Inc. Effector proteins and methods of use
WO2023230579A2 (en) * 2022-05-25 2023-11-30 Metagenomi, Inc. Supplementation of liver enzyme expression
WO2024020346A2 (en) * 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024042168A1 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2024107665A1 (en) * 2022-11-14 2024-05-23 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20190264186A1 (en) * 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1
EP3445856A1 (en) * 2016-04-19 2019-02-27 The Broad Institute Inc. Novel crispr enzymes and systems
AU2017407272B2 (en) * 2017-03-30 2024-06-13 Kyoto University Method for inducing exon skipping by genome editing
EP3612551B1 (en) * 2017-04-21 2024-09-04 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
EP3635113A4 (en) * 2017-06-05 2021-03-17 Fred Hutchinson Cancer Research Center GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND MANIPULATED NANOPARTICLES TO DELIVER TARGETED GENETIC THERAPIES
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
AU2018330197B2 (en) 2017-09-07 2022-09-01 Intima Bioscience, Inc. Nuclease systems for genetic engineering
SG11202003464VA (en) 2017-10-17 2020-05-28 Crispr Therapeutics Ag Compositions and methods for gene editing for hemophilia a
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
CN111954715A (zh) 2018-03-29 2020-11-17 菲特治疗公司 工程改造的免疫效应细胞和其用途
CA3109083A1 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
WO2020123887A2 (en) 2018-12-14 2020-06-18 Pioneer Hi-Bred International, Inc. Novel crispr-cas systems for genome editing
WO2020142754A2 (en) * 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
JP2022520428A (ja) 2019-02-14 2022-03-30 メタゲノミ アイピー テクノロジーズ,エルエルシー Ruvcドメインを有する酵素
US10982200B2 (en) 2019-02-14 2021-04-20 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CN110684823A (zh) 2019-10-23 2020-01-14 海南大学 一种基于试纸条的Cas12a酶的微生物快速诊断技术
CN110904239B (zh) 2019-12-25 2020-11-10 武汉博杰生物医学科技有限公司 肺癌相关分子标志物基因突变的检测试剂盒与检测方法
WO2021178934A1 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
CA3174557A1 (en) 2020-03-06 2021-09-10 Metagenomi, Inc. Class ii, type v crispr systems
JP2023533417A (ja) 2020-05-08 2023-08-03 メタゲノミ,インコーポレイテッド Ruvcドメインを有する酵素
MX2023002913A (es) 2020-09-11 2023-06-01 Metagenomi Inc Enzimas para edicion de bases.
WO2022159742A1 (en) 2021-01-22 2022-07-28 Metagenomi, Inc Novel engineered and chimeric nucleases
AU2022210762A1 (en) 2021-01-22 2023-08-24 Metagenomi, Inc. Novel engineered and chimeric nucleases
EP4281567A1 (en) 2021-01-25 2023-11-29 The Broad Institute Inc. Reprogrammable tnpb polypeptides and use thereof
CA3210361A1 (en) 2021-03-19 2022-09-22 Brian Thomas Multiplex editing with cas enzymes
BR112023024983A2 (pt) 2021-06-02 2024-04-30 Metagenomi Inc Sistemas crispr classe ii, tipo v

Also Published As

Publication number Publication date
AU2021231074C1 (en) 2024-06-27
CN116096876A (zh) 2023-05-09
US20220290187A1 (en) 2022-09-15
GB202219438D0 (en) 2023-02-01
KR20240036729A (ko) 2024-03-20
EP4114932A4 (en) 2024-03-13
KR20220150329A (ko) 2022-11-10
GB2603704B (en) 2023-02-15
MX2022011039A (es) 2022-12-13
WO2021178933A2 (en) 2021-09-10
GB2617658B (en) 2024-04-17
US20230227857A1 (en) 2023-07-20
KR102647766B1 (ko) 2024-03-13
JP2023517041A (ja) 2023-04-21
US20240093239A1 (en) 2024-03-21
GB202205584D0 (en) 2022-06-01
US11713471B2 (en) 2023-08-01
AU2024200614A1 (en) 2024-04-11
AU2021231074A1 (en) 2022-09-29
EP4114932A2 (en) 2023-01-11
WO2021178933A3 (en) 2021-12-23
GB2603704A (en) 2022-08-10
AU2021231074B2 (en) 2023-11-02
GB2617658A (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US11713471B2 (en) Class II, type V CRISPR systems
JP2023179468A (ja) Ruvcドメインを有する酵素
US20230416710A1 (en) Engineered and chimeric nucleases
KR20230021657A (ko) Ruvc 도메인을 포함하는 효소
JP2020517299A (ja) 縦列反復配列を有するドナーdna修復鋳型を使用する部位特異的なdna改変
WO2021178934A1 (en) Class ii, type v crispr systems
US20240301374A1 (en) Systems and methods for transposing cargo nucleotide sequences
CN113728097A (zh) 具有ruvc结构域的酶
US20240218339A1 (en) Class ii, type v crispr systems
WO2022066335A1 (en) Systems and methods for transposing cargo nucleotide sequences
KR20240049306A (ko) Ruvc 도메인을 갖는 효소
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
CN117693585A (zh) Ii类v型crispr系统
WO2023164590A2 (en) Fusion proteins
WO2022056301A1 (en) Base editing enzymes
WO2024026499A2 (en) Class ii, type v crispr systems
WO2023178115A2 (en) Engineered and chimeric nucleases
GB2617659A (en) Enzymes with RUVC domains

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230313

EEER Examination request

Effective date: 20230313

EEER Examination request

Effective date: 20230313

EEER Examination request

Effective date: 20230313